Deutsche Bank Aktiengesellschaft raised ACADIA Pharmaceuticals from a "hold" rating to a "buy" rating and raised their target price for the stock from $20.00 to $35.00 in a research note on Wednesday, May 21st. Finally, Wall Street Zen raised ACADIA Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Saturday, August 16th. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $28.88.